60 years of practical, independent and trusted advice
DTB, the UK’s independent drug and therapeutics bulletin, is celebrating its 60th anniversary. Since its launch as one of the first evidence-based medical publications, DTB has sought to enable healthcare professionals to make vital, impartial and trusted decisions on the harms and benefits of medicines. We reach thousands of healthcare professionals every year helping them to improve the health of patients. Over the next few months we will be publishing a series of special articles and interviews with a focus on the importance of drug bulletins.
In a series of podcasts to mark the 60th anniversary of DTB, we talk to some of DTB's Editorial Board members and other colleagues about their work and their involvement with DTB. In this interview, David Phizackerley (DTB deputy editor) talks to Barbara Mintzes (DTB associate editor) who is Associate Professor at the School of Pharmacy and Charles Perkins Centre at the University of Sydney, where she has worked since 2015. Her background is in epidemiology and the main focus of her work is on pharmaceutical policy, including the effects of direct-to-consumer advertising and physician-directed promotion on medicine use. Barbara talks about her interest in medicines policies, the impact of pharmaceutical and medical device company payments to clinicians, medicalisation of normal life, medicine safety scandals and the impact on those who have been harmed by medicines with a particular focus on women's health.
Life begins at 60 – James Cave, Editor for DTB, considers the challenges ahead for independent drug bulletins in this editorial Clarity to what was a confusing panoply of therapeutic choices – Sir Patrick Vallance, fomer DTB Editorial Board Member, reflects on his time at DTB Read the full issue now for free >>
Chronic hypertension in pregnancy – as part of the pregnancy series, Anja Johansen-Bibby discusses the impact and treatment of chronic hypertension Mandatory disclosure of all pharmaceutical and medical device companies’ payments to healthcare providers – Sidney Wolfe on learnings from the USA
“We can expect to see a significant increase in drugs coming into clinical use based on limited efficacy data and safety data that will be reliant on post-marketing surveillance and real world data…as well as an increase in…commercial arrangements with manufacturers. The need for independent scrutiny has never been more important.“ – Dr James Cave, Editor DTB